



**FOR IMMEDIATE RELEASE**

Tokyo, April 25, 2019

**Top-line Results of JTE-052 Ointment, JAK inhibitor,  
Phase 3 Clinical Study in Pediatric Patients with Atopic Dermatitis  
(Comparative Study) in Japan**

Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) today announce the top-line results of Phase 3 comparative study in pediatric patients with atopic dermatitis in Japan for JTE-052 (generic name: delgocitinib) ointment, a Janus kinase (JAK) inhibitor. Delgocitinib ointment was originated by JT and has been developed in Japan by JT and Torii under the terms of an agreement for co-development and marketing in Japan, signed on October 28, 2016.

This study is a double blind, randomized and parallel-group comparison study to evaluate the efficacy and safety of delgocitinib ointment in comparison to the vehicle over 4 weeks in pediatric patients with atopic dermatitis (aged 2 to <16), conducted in Japan. The top-line results show that the primary endpoint of efficacy, the percentage change of the mEASI score\* from baseline, has met superiority to the vehicle. The favorable tolerability profile on safety was obtained within the treatment period.

\* mEASI score (modified) is the score except for head and neck part from Eczema Area and Severity Index (EASI) score, a tool used to measure the extent area and severity of atopic dermatitis.

JT and Torii will aim to submit a marketing application for delgocitinib ointment in Japan, based on the results of this and other clinical studies. In addition, the new drug application in patients with atopic dermatitis (aged  $\geq 16$ ) was filed on January 31, 2019.

**ABOUT Atopic Dermatitis**

Atopic dermatitis is a chronic and pruritic inflammatory skin disease. It is thought to develop through exposure to various irritation or allergens for patients with a physiological abnormality of the skin (dry skin and abnormal skin barrier function).

###

*Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With over 63,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its*

*tobacco vapor products under the Ploom brand and various e-cigarette products under the Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit <https://www.jt.com/>.*

Contact for Japan Tobacco Inc.:

Masahito Shirasu, General Manager  
Media and Investor Relations Division  
Japan Tobacco Inc. Tokyo: +81-3-5572-4292  
E-mail: [jt.media.relations@jt.com](mailto:jt.media.relations@jt.com)

Contact for Torii Pharmaceutical Co., Ltd.:

Corporate Planning Department  
(Public Relations)  
Torii Pharmaceutical Co., Ltd.  
Tokyo: +81-3-3231-6814